Research & Development
Scientists develop portable SARS-CoV-2 sensor on a chip
"The sensor provided a rapid and sensitive detection platform with a detection limit of 57 pg/mL (3.7 copy/mL), 27-fold more sensitive than RT-PCR," wrote the authors, led by Heba Hussein, PhD, of the Animal Health Research Institute at the Agricultural Research Center in Giza, Egypt.
November 16, 2021
Paragon debuts more COVID-19 NGS tests
The tests include the CleanPlex angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2) panel, a multiplex polymerase chain reaction (PCR)-based targeted sequencing assay that analyzes genetic factors impacting COVID-19 infection susceptibility and disease severity. In addition, the CleanPlex SARS-CoV-2 Flex research panel detects mutations and additional genome coverage of the novel coronavirus.
October 18, 2020
As COVID-19 crisis continues, other infectious diseases threaten
As of March 16, the World Health Organization (WHO) had reported more than 137,000 confirmed cases and over 6,600 deaths worldwide from COVID-19, the respiratory disease caused by the SARS-CoV-2 virus. The diagnostics industry is rising to the challenge presented by the coronavirus pandemic, with test developers creating new assays to detect SARS-CoV-2 infection as lab operators ramp up throughput to meet skyrocketing demand.
March 17, 2020
ELISA blood test helps identify flu immunity
The researchers focused on 88 people in Nicaragua who were confirmed to be infected with pandemic H1N1 influenza A virus, as well as 300 people in their households who had contact with those infected. The investigators first used the ELISA blood test to measure pre-existing levels of antibodies produced against hemagglutinin (HA), a mushroom-shaped protein found on the surface of the influenza virus that is key to its infectivity. They then obtained additional blood samples 30 to 45 days later and acquired nasal and throat swabs to track who became infected with the flu virus.
June 3, 2019
InDevR's flu assay gets green light from FDA
The single multiplexed diagnostic can differentiate between seasonal and nonseasonal influenza A viruses, which is helpful for picking up on subtypes that could cause a pandemic, such as H7N9 and H5N1. The assay provides results on the same day of testing, according to the company.
April 30, 2019
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Quest Diagnostics offers suite of services for transplant patients and living donors
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Page 1 of 1